English中文

News

Home > News > Marketing Activity >

MED-EL acquires bone conduction technology from Otorix AB

writer:admin pubdate:2016-08-11 16:58 view:()

MED-EL has announced on July 15 the acquisition of the Adjoin bone conduction hearing system from the Swedish medical device company Otorix.

According to the press release the system is a novel non-surgical solution for conductive hearing loss that will enable MED-EL to reach more candidates while expanding its portfolio of hearing solutions. The system comprises two parts: an adhesive adapter and audio processor which are worn together discretely behind the ear. It is an excellent option for people with conductive hearing loss who are unsuitable for, or not wishing to undergo, bone conduction implant surgery. All system components are easy-to-use and maintain and transmit sound to the inner ear with no applied skin pressure.

Patrik Westerkull, founder and CEO of Otorix, said: “It was my ambition to take the bone conduction field further. With the Adjoin technology we finally have a non-implantable bone conduction solution that does not require pressure on the skin for effective and reliable sound transmission, while also providing excellent comfort and great aesthetics. I look forward to working with MED-EL on bringing this fantastic product to the market.”

The new product will be the first non-implantable hearing solution produced by MED-EL which already offers a wide range of implantable hearing solutions. This includes the world´s first active bone conduction implant – the BONEBRIDGE. The new combination of technology and expertise in this sector will support MED-EL’s growth in key markets.

Dr. Ingeborg Hochmair, global CEO of MED-EL, said: “This exciting technology will be an important supplement to our range of implantable solutions including the BONEBRIDGE. It fills the unmet need for a non-implantable bone conduction solution and firmly enforces MED-EL’s mission to overcome hearing loss as a barrier to communication and quality of life.”

First clinical trial results have been extremely successful and development of the product continues with an expected launch date in 2017.

Source: MED-EL

Copyright © 2013 Shenzhen Bellsing Acoustic Technology Co., Ltd. All rights reserved.粤ICP备16051745号